CSNK2A2

Across TCGA pan-cancer cohorts, CSNK2A2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CSNK2A2 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CSNK2A2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CSNK2A2 expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

PDAC, GBM, and COAD are the cancer types where CSNK2A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.301	0.614	<.001	39	view →
GBM	DFS	Quartile	All	0.490	0.247	.012	11	view →
COAD	DFS	Median	IV	0.432	0.944	.012	6	view →
LSCC	OS	Quartile	II,III,IV	1.000	0.767	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CSNK2A2–PDAC (DFS)

Open the PDAC breakdown →